My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    EPOXOMICIN (BU 4061T)
    EPOXOMICIN (BU 4061T)

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0689
    CAS #: 134381-21-8Purity ≥98%

    Description: Epoxomicin (formerly also known as BU-4061T) is a novel, potent, selective, cell-permeable and irreversible proteasome inhibitor with anti-inflammatory activity, it inhibits primarily the CH-L activity of the 20S proteasome, while T-L and PGPH catalytic activities are also inhibited at 100- and 1000-fold reduced rate. The novel α-epoxy ketone moiety of Epoxomicin forms covalent bonds with residues in particular catalytic subunits of the enzyme, disabling activity.

    References: Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)554.72
    FormulaC28H50N4O7
    CAS No.134381-21-8
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 100 mg/mL (180.3 mM)
    Water: <1 mg/mL
    Ethanol: 100 mg/mL (180.3 mM)
    Other infoChemical Name: (2S,3S)-2-[[(2S,3S)-2-[Acetyl(methyl)amino]-3-methylpentanoyl]amino]-N-[(2S,3R)-3-hydroxy-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]-3-methylpentanamide
    InChi Key: DOGIDQKFVLKMLQ-JTHVHQAWSA-N
    InChi Code: InChI=1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17-,18+,20-,21-,22-,23-,28+/m0/s1
    SMILES Code: CC[[email protected]](C)[[email protected]](NC([[email protected]@H](N(C(C)=O)C)[[email protected]@H](C)CC)=O)C(N[[email protected]@H]([[email protected]](O)C)C(N[[email protected]@H](CC(C)C)C([[email protected]]1(C)OC1)=O)=O)=O
    SynonymsBU-4061T; BU 4061T; BU4061T; EPOXOMICIN;


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2
    In Vitro

    In vitro activity: Epoxomicin covalently binds to the LMP7, X, MECL1, and Z catalytic subunits of the proteasome. Epoxomicin (100 nM) results in a 30-fold increase in the levels of p53 protein, a known target of the proteasome, in HUVECs. Epoxomicin (10 μM) results in the accumulation of ubiquitinated proteins in HeLa cells. Epoxomicin (10 μM) inhibits IκBα degradation by 10-fold in HeLa cells. Epoxomicin (10 μM) produces a significant dose-dependent reduction in TNF-α-stimulated NF-κB DNA-binding activity in HeLa cells. Epoxomicin inhibits proliferating of EL4 lymphoma cells with biotinylated chimerae with IC50 of 4 nM. Epoxomicin (1 μM) leads to a reduction of LCMV GP33 presentation and an enhancement of GP276 presentation.

    In VivoEpoxomicin (0.58 mg/kg per day) reduces the CS response by 44% relative to the control group of mice treated with vehicle alone. Epoxomicin (2.9 mg/kg) potently inhibits the irritant-associated inflammatory response by 95% when ear edema measurements are made 24 hours postchallenge in mice.
    Animal modelBALB/c mice
    Formulation & DosageDissolved in 10% DMSO/PBS; 2.9 mg/kg; i.p. injection
    ReferencesProc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.


    These protocols are for reference only. InvivoChem does not independently validate these methods.

    EPOXOMICIN

    Accumulation of p53 (A) and ubiquitinated proteins (B) in epoxomicin-treated cells. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.
     
     

    EPOXOMICIN

    Epoxomicin inhibits activation of NF-κB. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.
     

    EPOXOMICIN

    Epoxomicin inhibits inflammation in vivo. Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10403-8.

    EPOXOMICIN

    EPOXOMICIN

    EPOXOMICIN


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?